

1 **Long COVID in Cancer patients: Preponderance of Symptoms in Majority of Patients over**
2 **Long Time Period.**

3

4 Hiba Dagher¹, Anne-Marie Chaftari¹, Ishwaria M. Subbiah², Alexandre E. Malek¹, Ying Jiang¹,
5 Peter Lamie³, Bruno Granwehr¹, Teny John¹, Eduardo Yopez¹, Jovan Borjan⁴, Cielito Reyes⁵,
6 Mary Flores⁵, Fareed Khawaja¹, Mala Pande⁶, Noman Ali³, Raniv Rojo⁷, Daniel D. Karp⁸, Ray
7 Hachem¹, Issam Raad¹

8

9

10 ¹Department of Infectious Diseases, Infection Control and Employee Health, The University of
11 Texas MD Anderson Cancer Center, Houston, Texas, USA

12

13 ²Integrative Medicine Program, The University of Texas MD Anderson Cancer Center, Houston,
14 Texas, USA

15

16 ³Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas,
17 USA

18

19 ⁴Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston,
20 Texas, USA

21

22 ⁵Emergency Medicine-Research, The University of Texas MD Anderson Cancer Center,
23 Houston, Texas, USA

24

25 ⁶Gastroenterology Research, The University of Texas MD Anderson Cancer Center, Houston,
26 Texas, USA

27

28 ⁷Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston,
29 Texas, USA

30

31 ⁸Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas,
32 USA

33

34

35 **Corresponding author:** Anne-Marie Chaftari, Department of Infectious Diseases, Infection
36 Control and Employee Health, Unit 1460, The University of Texas MD Anderson Cancer Center,
37 1515 Holcombe Blvd., Houston, TX 77030, USA. Tel: 713-792-3491, Email:
38 achaftari@mdanderson.org

39

40 **Keywords:** Cancer patients, immunocompromised, COVID-19, long-COVID, sequelae.

41

42

43 **Abstract:**

44 **Background:**

45 An increasing number of observational studies have reported the persistence of symptoms
46 following recovery from acute COVID-19 disease in non-cancer patients. The long-term
47 consequences of COVID-19 are not fully understood particularly in the cancer patient
48 population. The purpose of this study is to assess post-acute sequelae of SARS-CoV-2 infection
49 (PASC) in cancer patients following acute COVID-19 recovery.

50

51 **Methods:**

52 We identified cancer patients at MD Anderson Cancer Center who were diagnosed with COVID-
53 19 disease between March 1, 2020 and Sept 1, 2020 and followed them till May 2021. To
54 assess PASC, we collected patients reported outcomes through questionnaires that were sent
55 to patients daily for 14 days after COVID-19 diagnosis then weekly for 3 months, and then
56 monthly thereafter. We also reviewed patients' electronic medical records to capture the the
57 persistence or emergence of new COVID19-related symptoms reported during any clinic or
58 hospital encounter beyond 30 days of the acute illness and up to 14 months.

59

60 **Results:**

61 We included 312 cancer patients with a median age of 57 years (18-86). The majority of
62 patients had solid tumors (75%). Of the 312 patients, 188 (60%) reported long COVID-19
63 symptoms with a median duration of 7 months and up to 14 months after COVID-19 diagnosis.
64 The most common symptoms reported included fatigue (82%), sleep disturbances (78%),
65 myalgias (67%) and gastrointestinal symptoms (61%), followed by headache, altered smell or
66 taste, dyspnea (47%) and cough (46%). A higher number of females reported a persistence of
67 symptoms compared to males (63% vs 37%; $p=0.036$). Cancer type, neutropenia,

68 lymphocytopenia, and hospital admission during acute COVID-19 disease were comparable in
69 both groups. Among the 188 patients with PASC, only 16 (8.5%) were readmitted for COVID-
70 related reasons.

71

72 **Conclusions:**

73 More than one out of two cancer patients, and more likely females, report PASC that may
74 persist beyond 6 months and even one year. The most common symptoms are non-respiratory
75 and consist of fatigue, sleep disturbance, myalgia and gastro-intestinal symptoms. Most of the
76 cancer patients with PASC were managed on outpatient basis with only 8,5% requiring a
77 COVID-19 related re-admission.

78

79 **Introduction**

80
81 Clinical outcomes of COVID-19 in patients with cancer remains an area of active study
82 with several studies showing more severe outcomes and associated risk factors such as pre-
83 existing comorbidities, cancer stage and therapy, and immunocompromised state, compared to
84 the non-cancer population¹⁻⁴.

85 The earliest studies characterized the acute and sub-acute effects of COVID-19 on
86 multiple organ systems⁵ while more recent work has raised concern on the chronic symptoms
87 attributed to COVID-19 that persist beyond the expected recovery period^{6,7} with some
88 symptoms similar to those experienced during the recovery of other viral illnesses⁸⁻¹³.

89 The long-term consequences of COVID-19 remain to be fully understood and there is no
90 unequivocal consensus on the definition of post-acute sequelae of SARS-CoV-2 infection
91 (PASC), with one adopted definition being the persistence of symptoms or new delayed
92 complications that develop at least 4 weeks after a COVID-19 diagnosis^{7,14,15}. The reported
93 prevalence of PASC widely varies from 10% up to 87% in the general population^{7-9,16-18} and
94 there is limited data available on PASC in cancer patients and how it affects their cancer
95 progression, care and treatment.

96 Several studies suggest the persistence of symptoms past 30 days in patients with
97 severe initial COVID-19 symptoms and those that were hospitalized due to COVID-19^{6,17,18},
98 while other studies have shown a prevalence of PASC among COVID-19 outpatients as well
99 ^{8,9,19}. Since cancer patients fall in a higher COVID-19 risk group¹ and in order to provide a better

100 understanding of post-COVID-19 management among cancer patients, we sought to
101 characterize the patterns of long COVID-19 in the specific cancer patient population.

102
103 **Methods**

104 We identified patients with cancer receiving care at the University of Texas MD Anderson
105 Cancer Center who were also diagnosed with COVID-19 disease between March 1, 2020 and
106 Sept 1, 2020. We followed these patients as longitudinal cohort through patient-reported
107 outcomes (PRO)-based remote symptom monitoring along with usual care with clinician visits.
108 Patients were followed from March 2020 until May 31, 2021. Patient questionnaires were sent
109 out remotely daily for 14 days after COVID-19 diagnosis then weekly for 3 months, and then
110 monthly thereafter. Chart reviews were conducted for each patient's encounter that included
111 visits to our acute cancer care center, hospital re-admission, or clinic visit. Re-admissions were
112 classified as either related or non-related to COVID-19 based on the reason for hospitalization
113 as well as the reported signs and symptoms. PASC or long COVID-19 was defined as the
114 persistence of COVID-19 related symptoms beyond 30 days of diagnosis or the emergence of
115 new COVID-19-related symptoms reported during a hospital or clinic encounter throughout the
116 follow-up period that extended up to 14 months. COVID-19 related symptoms included among
117 others fatigue, cough, chest tightness, dyspnea, headache, fever, altered smell or taste,
118 myalgias, gastrointestinal symptoms (such as nausea, vomiting or diarrhea), sleep disturbance,
119 and limitations with activities of daily living (ADLs).

121

122
123
124
125
126

127
128
129

130
131
132
133
134
135

Statistical analysis

Categorical variables were compared using chi-square or Fisher's exact test, as appropriate.

Continuous variables were compared using Wilcoxon rank sum test. All the tests were 2-sided with a significance level of 0.05. The statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Results

Among the 602 patients who were diagnosed with COVID-19 during the study period, longitudinal data was collected on 312 patients that included 188 patients who developed PASC having reported symptoms that persisted at least 30 days after COVID-19 diagnosis and 124 who did not. The remaining patients (290) could not be followed or assessed beyond 30 days. The female gender rate was significantly higher in the PASC group compared to the non-PASC group (63% vs 51%; $p=0.036$). The age and race were similar in both groups. The median age was 57 and 27% of both groups were above 65 years old. While the rate of hypertension was higher in the non-PASC group (56% vs 37%; $p<0.001$), the rate of other comorbidities such as COPD and congestive heart failures were similar in both groups. Furthermore, the type of underlying cancer was similar in both groups with the majority of patients having solid tumors. In addition, the rate of neutropenia, lymphocytopenia, lower respiratory tract infections, hypoxia, oxygen requirement, inflammatory biomarkers, COVID-19 related hospital admissions, multi-

148 organ failure as well as medical management of COVID-19 were similar in both groups (Table
149 1). The 312 patients who were assessed beyond 30 days were followed for a median duration
150 of 7 months and up to 14 months.

151 The most commonly reported symptoms among the 188 patients who developed PASC
152 consisted of fatigue (82%), sleep disturbance (78%), myalgias (67%), gastro-intestinal
153 symptoms (62%), headache (47%), altered smell and taste (47%), dyspnea (47%) and cough
154 (46%) (Figure 1).

155 Among the 188 cancer patients who reported PASC, 59 patients (31%) were re-admitted to the
156 hospital during the follow-up period and beyond 30 days of acute illness, only 16 (8.5%) of the
157 patients with PASC had a COVID-related re-admission.

158

159

160 **Discussion**

161 Our data showed that 60% of 312 cancer patients diagnosed with COVID and
162 followed up for a median duration of 7-month [up to 14-month] developed PASC.

163 Females were more likely to report persistence of symptoms compared to
164 males. However, cancer type, age, neutropenia, lymphocytopenia, hypoxia, severe
165 disease, multiorgan failure, various interventions, or hospital admission during
166 acute COVID-19 disease were not associated with higher risk of long-COVID in

167 our study group. While hypertension was more significantly associated with no
168 PASC during follow-up. The most common PASC symptoms were fatigue, sleep
169 disturbances, myalgias and gastrointestinal symptoms. Furthermore, among PASC
170 patients who were re-hospitalized for any cause during the follow-up, the
171 admission was COVID-related in only 27%.

172
173 In a manner similar to our current study, the CDC reported that 60% of patients
174 with immunosuppressive conditions continue to have COVID-19 symptoms
175 beyond the acute illness¹⁹. In the same CDC study, hypertension was found to be
176 significantly less often associated with PASC which is another similar finding
177 noted in our study. It is unknown from a pathophysiologic perspective as to why
178 hypertension, which is a risk factor for acute and severe COVID-19 should be less
179 associated with PASC. However given the fact that the pathogenesis of acute
180 COVID-19 is related to the interaction of the viral spike protein with the
181 angiotensin-converting enzyme 2 (ACE 2), one could postulate that this pathway
182 does not play an important role in long COVID compared to the residual

183 inflammatory processes that seem to continue to occur in PASC^{7,20}. Similarly,
184 males are at greater risk of acute complications and death associated with acute
185 COVID-19 possibly related to higher ACE 2 expression levels in the male
186 gender²⁰⁻²². However, in our study females were more likely to develop PASC also
187 suggesting a different mechanism of action for PASC besides ACE 2 expression⁷.
188
189 The existing literature has also shown a higher prevalence of PASC and a longer
190 time to recovery among those with more severe COVID -19 who required hospital
191 admission and medical interventions^{6,17,18}. However there has been several
192 reports of PASC among patients with self-reported COVID -19 who had mild
193 acute illness and were never hospitalized^{8,9,19,23}. In our study, severe acute COVID
194 associated with hypoxia, multiorgan failure, hospital admission or underlying risk
195 factors for the progression of acute COVID-19 in cancer patients such as
196 neutropenia, lymphocytopenia, hematologic malignancy or older age were not
197 associated with increased risk of long COVID.

198

199 In the general population and following acute COVID-19, PASC symptoms
200 occurred at a variable rate ranging from 10% to 87%^{7-9,16-18}. In a manner similar to
201 our results, fatigue was the most prevalent PASC symptom in many reports
202 occurring in up to 87% of COVID-19 patients compared to 82% in our patient
203 population^{7,9,17,18}. Other common PASC symptoms reported in our study such as
204 sleep disturbances, myalgias, gastrointestinal symptoms, headache, loss of smell
205 and taste, dyspnea and cough were also widely and commonly reported in the
206 COVID-19 literature^{7-9,16-18}. However, all of these symptoms commonly occur in
207 patients with underlying malignancy who continue to receive treatment with
208 conventional chemotherapy, radiotherapy and immunotherapy (including
209 checkpoint inhibitors). Hence, the rates of some of these PASC symptoms in the
210 cancer patient population could be exaggerated and partially related to the
211 underlying malignancy and its treatment.

212

213 In our cancer patient population, PASC was not associated with a high rate of
214 COVID 19 related hospital admissions during the follow-up. All cause admissions

215 occurred at a rate of 31% among our cancer patients with PASC and among those
216 who were admitted only 27% were admitted because of COVID-19 related
217 reasons. Hence, among all PASC patients in our study only 8.5% were admitted
218 for COVID 19 related reasons. Furthermore, some of those few that were admitted
219 for COVID-19 related reasons could have had reinfection with a new variant
220 during the prolonged follow-up period or reactivation related to their
221 immunosuppressed status. Hence, even in our high risk cancer patient population
222 most of the symptoms associated with PASC were managed for the most part on an
223 outpatient basis without the need for hospital admission.

224
225 Our study has its limitations. First, the retrospective nature of this study limits any
226 firm conclusions about factors directly contributing to PASC in our COVID-19
227 cancer patients. Second, this is a single center study which could also limit the
228 generalization of our results. Third, the subjective nature of surveys in the absence
229 of quality of life assessment scales and other verified objective scales to assess
230 reported PASC criteria could also limit our conclusions. Finally, the presence of

231 several confounding causes of hospital admissions and overlapping symptoms in
232 cancer patients that may be due to their underlying disease, aggressive treatments
233 and comorbidities present their own challenge in identifying PASC among cancer
234 patients post their COVID-19 diagnosis.

235
236 In conclusion, long COVID occurred in the majority of our cancer patients
237 diagnosed with acute COVID-19 with a preponderance of symptoms (such as
238 fatigue, sleep disturbances, and gastrointestinal symptoms) over a long time
239 period. Most of the patient's with long COVID/PASC were fairly and adequately
240 managed on outpatient basis without the need for hospital admission. Besides the
241 female gender, we found no other underlying condition or severity of illness during
242 acute COVID-19 that would predict PASC.

243

Table 1. Comparing COVID-19 cancer patients with and without long-term symptoms (at least 30 days after their COVID-19 diagnosis).

Variables	Having PASC		p-value
	No	Yes	
	(n=124) N (%)	(n=188) N (%)	
Age (years), median (range)	57 (18-85)	57 (21-86)	0.47
Age ≥ 65	33 (27)	50 (27)	> .99
Gender			0.036
Male	61 (49)	70 (37)	
Female	63 (51)	118 (63)	
Race			0.45
Caucasian	66 (53)	102 (54)	
Black	24 (19)	26 (14)	
Hispanic	28 (23)	52 (28)	
Asian	5 (4)	8 (4)	
Other	1 (1)	0 (0)	
Prior COPD/Bronchiolitis obliterans	4 (3)	7 (4)	> .99
History of hypertension	70 (56)	69/187 (37)	< .001
History of heart failure	3 (2)	5/186 (3)	> .99
Type of cancer			0.92
Hematological malignancy	31 (25)	48 (26)	
Solid tumor	93 (75)	140 (74)	
Hypoxia at diagnosis	25 (20)	23/180 (13)	0.08
Oxygen flow at diagnosis			0.20
High flow	6/30 (20)	6/43 (14)	
Low flow	15/30 (50)	15/43 (35)	
None	9/30 (30)	22/43 (51)	
Non-invasive ventilation at diagnosis	16 (13)	13/179 (7)	0.10
Lab values at COVID-19 diagnosis			
ALC < 1 K/uL	44/74 (59)	57/94 (61)	0.88
ANC < 0.5 K/uL	5/75 (7)	5/89 (6)	> .99
Hemoglobin < 10 g/dL	23/65 (35)	16/78 (21)	0.06
LDH ≥ 250 U/L	29/58 (50)	41/67 (61)	0.21
D-dimer ≥ 1 mcg/ml	28/54 (52)	27/61 (44)	0.42
Ferritin ≥ 500 ng/ml	30/54 (56)	36/59 (61)	0.56
CRP ≥ 40 mg/L	32/56 (57)	43/63 (68)	0.21
IL-6 ≥ 25 pg/ml	18/41 (44)	20/48 (42)	0.83
LRTI at diagnosis or progression to LRTI	29 (23)	35/182 (19)	0.38
COVID-related hospital admission	53 (43)	68 (36)	0.24
Remdesivir treatment	17 (14)	18 (10)	0.26
IL-6 pathway inhibitors - Tocilizumab	8 (6)	5 (3)	0.10
Convalescent plasma	8 (6)	15 (8)	0.61

Steroids	18 (15)	19 (10)	0.24
Multi-organ failure	6/121 (5)	8/180 (4)	0.84

Note:

(Just let you know) A multivariate logistic regression analysis showed history of hypertension was the only factor that was independently associated with long-term symptoms ($p < .001$), but as a protector (OR=0.43,

95% CI=0.27 to 0.69), not as a risk factor.

244


245

246

247

248

249 **Figure 1. Post-Acute Sequela of SARS-CoV-2 Infection (PASC)-related symptoms**
250 **(N=188).**
251



252

253 **ACKNOWLEDGMENTS**

254 We thank Ms. Salli Saxton, Department of Infectious Diseases, Infection Control and Employee Health,
255 MD Anderson Cancer Center, Houston, for helping with the submission of the manuscript.

256 This research was supported by the National Institutes of Health/National Cancer Institute under award
257 number P30CA016672, which supports MD Anderson Cancer Center's Clinical Trials Office.

258

259 **References**

- 260
- 261 1. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. *Cancer Discov.* 2020;10(6):783-791.
- 262
- 263
- 264 2. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ.* 2020;369:m1966.
- 265
- 266 3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA.* 2020;323(13):1239-1242.
- 267
- 268
- 269
- 270
- 271 4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054-1062.
- 272
- 273
- 274 5. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat Med.* 2020;26(7):1017-1032.
- 275
- 276 6. Barman MP, Rahman T, Bora K, Borgohain C. COVID-19 pandemic and its recovery time of patients in India: A pilot study. *Diabetes Metab Syndr.* 2020;14(5):1205-1211.
- 277
- 278 7. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med.* 2021;27(4):601-615.
- 279
- 280 8. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect.* 2021;27(1):89-95.
- 281
- 282 9. Goertz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? *ERJ Open Res.* 2020;6(4).
- 283
- 284 10. Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. *J Rehabil Med.* 2020;52(5):jrm00063.
- 285
- 286
- 287
- 288 11. Hui DS, Joynt GM, Wong KT, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. *Thorax.* 2005;60(5):401-409.
- 289
- 290
- 291 12. Kausler DH, Lichty W, Hakami MK, Freund JS. Activity duration and adult age differences in memory for activity performance. *Psychol Aging.* 1986;1(1):80-81.
- 292
- 293 13. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. *BMC Neurol.* 2011;11:37.
- 294
- 295
- 296 14. Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. *JAMA.* 2020;324(22):2251-2252.
- 297
- 298
- 299 15. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ.* 2020;370:m3026.
- 300
- 301 16. Bowles KH, McDonald M, Barron Y, Kennedy E, O'Connor M, Mikkelsen M. Surviving COVID-19 After Hospital Discharge: Symptom, Functional, and Adverse Outcomes of Home Health Recipients. *Ann Intern Med.* 2021;174(3):316-325.
- 302
- 303
- 304 17. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in Patients After Acute COVID-19. *JAMA.* 2020;324(6):603-605.
- 305
- 306 18. Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *J Med Virol.* 2021;93(2):1013-1022.
- 307
- 308

- 309 19. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for
310 Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate
311 Health Care Systems Network - United States, March-June 2020. *MMWR Morb Mortal*
312 *Wkly Rep.* 2020;69(30):993-998.
- 313 20. Kaseb AO, Mohamed YI, Malek AE, et al. The Impact of Angiotensin-Converting
314 Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection.
315 *Pathogens.* 2021;10(3).
- 316 21. Jin JM, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on
317 Severity and Mortality. *Front Public Health.* 2020;8:152.
- 318 22. Viveiros A, Rasmuson J, Vu J, et al. Sex differences in COVID-19: candidate pathways,
319 genetics of ACE2, and sex hormones. *Am J Physiol Heart Circ Physiol.*
320 2021;320(1):H296-H304.
- 321 23. Tenforde MW, Billig Rose E, Lindsell CJ, et al. Characteristics of Adult Outpatients and
322 Inpatients with COVID-19 - 11 Academic Medical Centers, United States, March-May
323 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(26):841-846.
324